The Institute for Clinical and Economic Review announced a Draft Evidence Report focused on the comparative clinical effectiveness of three antiandrogen therapies for prostate cancer.
The report analyzes abiraterone acetate, apalutamide and enzalutamide, as well as the value of enzalutamide and apalutamide.
According to a press release, the report on draft voting questions are open for comment until 5 p.m. EST Aug. 9.
ICER’s report will also be discussed at a public meeting of the Midwest Public Advisory Council in September.
Stakeholders can submit their comments by emailing email@example.com.
To read the Draft Evidence Report, click here.